FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061030607> ?p ?o ?g. }

• W2061030607 endingPage "71" @default.
• W2061030607 startingPage "63" @default.
• W2061030607 abstract "Triple antibiotic ointment (TAO) containing neomycin, polymyxin B, and bacitracin was launched in the 1950s in the United States (USA) as a prescription product and then was used over the counter (OTC) since the 1970s (USA) to prevent superficial wound infections. In Australia, TAO has been restricted to prescription use. This study 1) determined cross-resistance patterns of neomycin compared with other aminoglycosides; 2) determined the level and trend of resistance to TAO and individual components especially versus mupirocin-resistant strains (USA); and 3) established the baseline TAO activity level against pathogens from Australia. A total of 200 strains (≥50% gentamicin-resistant) from the United States were used for the cross-resistance study including Staphylococcus aureus (110), coagulase-negative staphylococci (CoNS; 50), Pseudomonas aeruginosa (10), Escherichia coli (20), and other Enterobacteriaceae (10) tested against TAO, bacitracin, polymyxin B, neomycin, amikacin, gentamicin, streptomycin, tobramycin, and mupirocin. Fifty gentamicin-resistant isolates from each year (1997–2002) were used to determine the activity of TAO over time. Baseline resistance rates of TAO among 300 Australian isolates (AGARS Program, 2002–2003) were also studied. Reference broth microdilution methods were used in all phases of this study. At a 1:100 dilution of the ointment concentration, TAO inhibited all CoNS, Pseudomonas aeruginosa, and Enterobacteriaceae isolates, and resistance to TAO among Staphylococcus aureus at this concentration was only 5% in the cross-resistance study. Patterns of susceptibility in the United States did not significantly vary from 1997 to 2002. Australian pathogens showed that TAO was 98% active against methicillin-resistant Staphylococcus aureus and 100% for Enterobacteriaceae, methicillin-susceptible S. aureus, CoNS, and P. aeruginosa, the rates equivalent to those observed in the United States. Mupirocin-resistant S. aureus (5%) and CoNS (47%) were all TAO-susceptible. All Gram-negative species were also mupirocin-resistant, but inhibited by neomycin and/or polymyxin B components of TAO. In conclusion, aminoglycoside resistance patterns differ significantly, and none of the commonly tested agents could accurately predict neomycin resistance. TAO resistance was rare in the United States after extensive OTC use and was not adversely influenced by decades of parenteral aminoglycoside use. Australian surveillance showed high levels of TAO susceptibility in sampled isolates as a baseline for possible OTC availability. TAO maintains a wider spectrum of activity compared with mupirocin and was usable against mupirocin-resistant Gram-positive strains." @default.
• W2061030607 created "2016-06-24" @default.
• W2061030607 creator A5001906344 @default.
• W2061030607 creator A5022901834 @default.
• W2061030607 creator A5034547261 @default.
• W2061030607 creator A5044679653 @default.
• W2061030607 creator A5053492923 @default.
• W2061030607 creator A5088975071 @default.
• W2061030607 date "2006-01-01" @default.
• W2061030607 modified "2023-09-28" @default.
• W2061030607 title "Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia" @default.
• W2061030607 cites W1630972714 @default.
• W2061030607 cites W1929414355 @default.
• W2061030607 cites W1976804437 @default.
• W2061030607 cites W1985490743 @default.
• W2061030607 cites W1985514510 @default.
• W2061030607 cites W1991734539 @default.
• W2061030607 cites W1998498230 @default.
• W2061030607 cites W1999808134 @default.
• W2061030607 cites W2022766724 @default.
• W2061030607 cites W2027813901 @default.
• W2061030607 cites W2045089570 @default.
• W2061030607 cites W2054222445 @default.
• W2061030607 cites W2073736583 @default.
• W2061030607 cites W2094956788 @default.
• W2061030607 cites W2101751962 @default.
• W2061030607 cites W2103417372 @default.
• W2061030607 cites W2103431426 @default.
• W2061030607 cites W2106096118 @default.
• W2061030607 cites W2108934927 @default.
• W2061030607 cites W2110193575 @default.
• W2061030607 cites W2116665651 @default.
• W2061030607 cites W2123964473 @default.
• W2061030607 cites W2142263666 @default.
• W2061030607 cites W2148313362 @default.
• W2061030607 cites W2152805553 @default.
• W2061030607 cites W2157346890 @default.
• W2061030607 cites W2157435775 @default.
• W2061030607 cites W2161700596 @default.
• W2061030607 cites W2171146225 @default.
• W2061030607 cites W2202948057 @default.
• W2061030607 cites W4230276422 @default.
• W2061030607 cites W4242458779 @default.
• W2061030607 cites W4255823349 @default.
• W2061030607 doi "https://doi.org/10.1016/j.diagmicrobio.2005.08.009" @default.
• W2061030607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16368476" @default.
• W2061030607 hasPublicationYear "2006" @default.
• W2061030607 type Work @default.
• W2061030607 sameAs 2061030607 @default.
• W2061030607 citedByCount "32" @default.
• W2061030607 countsByYear W20610306072012 @default.
• W2061030607 countsByYear W20610306072014 @default.
• W2061030607 countsByYear W20610306072015 @default.
• W2061030607 countsByYear W20610306072016 @default.
• W2061030607 countsByYear W20610306072017 @default.
• W2061030607 countsByYear W20610306072018 @default.
• W2061030607 countsByYear W20610306072020 @default.
• W2061030607 countsByYear W20610306072021 @default.
• W2061030607 countsByYear W20610306072022 @default.
• W2061030607 countsByYear W20610306072023 @default.
• W2061030607 crossrefType "journal-article" @default.
• W2061030607 hasAuthorship W2061030607A5001906344 @default.
• W2061030607 hasAuthorship W2061030607A5022901834 @default.
• W2061030607 hasAuthorship W2061030607A5034547261 @default.
• W2061030607 hasAuthorship W2061030607A5044679653 @default.
• W2061030607 hasAuthorship W2061030607A5053492923 @default.
• W2061030607 hasAuthorship W2061030607A5088975071 @default.
• W2061030607 hasConcept C176947019 @default.
• W2061030607 hasConcept C2775832221 @default.
• W2061030607 hasConcept C2777052132 @default.
• W2061030607 hasConcept C2777637488 @default.
• W2061030607 hasConcept C2778246068 @default.
• W2061030607 hasConcept C2778974779 @default.
• W2061030607 hasConcept C2779489039 @default.
• W2061030607 hasConcept C2779841869 @default.
• W2061030607 hasConcept C2779860364 @default.
• W2061030607 hasConcept C2780026444 @default.
• W2061030607 hasConcept C2780675486 @default.
• W2061030607 hasConcept C2780950330 @default.
• W2061030607 hasConcept C4937899 @default.
• W2061030607 hasConcept C501593827 @default.
• W2061030607 hasConcept C523546767 @default.
• W2061030607 hasConcept C54355233 @default.
• W2061030607 hasConcept C71924100 @default.
• W2061030607 hasConcept C86803240 @default.
• W2061030607 hasConcept C89423630 @default.
• W2061030607 hasConcept C94665300 @default.
• W2061030607 hasConceptScore W2061030607C176947019 @default.
• W2061030607 hasConceptScore W2061030607C2775832221 @default.
• W2061030607 hasConceptScore W2061030607C2777052132 @default.
• W2061030607 hasConceptScore W2061030607C2777637488 @default.
• W2061030607 hasConceptScore W2061030607C2778246068 @default.
• W2061030607 hasConceptScore W2061030607C2778974779 @default.
• W2061030607 hasConceptScore W2061030607C2779489039 @default.
• W2061030607 hasConceptScore W2061030607C2779841869 @default.
• W2061030607 hasConceptScore W2061030607C2779860364 @default.
• W2061030607 hasConceptScore W2061030607C2780026444 @default.
• W2061030607 hasConceptScore W2061030607C2780675486 @default.

• next